Skip to content
Wednesday 12 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,844.19
-0.17%
DAX
26,391.42
0.00%
CAC 40
8,714.94
0.00%
STOXX 50
6,551.22
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
What is City Talk? City Talk allows marketers to connect directly with our audience by publishing content on morningwire.eu
Friday 07 October 2022 10:34 am  |  Updated:  Tuesday 11 October 2022 3:08 pm

Advances in eye health

By: May Griffith

Add as a preferred source on Google
Dissecting slaughterhouse pig eyes that we use for testing biomaterials, e.g. suturing practice.

May Griffith, PhD, Marie-Claude Robert, MD, Samir Jabbour, MD, and Isabelle Brunette, MD Department of Ophthalmology, Université de Montréal

The first-in-human attempt to regenerate the human cornea was a team effort led by May Griffith, who is currently a Université de Montréal (UdeM) professor of ophthalmology. Together with Isabelle Brunette and the Swedish clinical trial team led by Per Fagerholm, they reported the successful regeneration of the human cornea in a clinical trial of 10 Swedish patients.

A follow-up study was completed on six patients at high risk of rejecting conventional human donor cornea transplantation in collaboration with corneal surgeons at the LV Prasad Eye Institute in India and the Filatov Institute of Eye Diseases and Tissue Therapy in Ukraine. The cell-free implants were able to stimulate the patient’s own stem cells to regrow or regenerate new corneal tissue and nerves.

Patients with ulceration and scarring after severe infection showed the best outcomes after surgery with cell-free implants that stimulated the patients’ corneas to regrow new tissue in place of the removed
pathologic tissue.

Bursting pressure testing to ensure biomaterials will seal defects.

Vaccines have always been highly successful at reaching the masses. Together with Moorfields
Eye Hospital’s cornea specialist, Bruce Allan, and the UdeM team have been focusing on delivering an
injectable solution to seal perforations and act as an alternative to partial thickness transplantation. Proof of concept in animal studies shows promising results.

The development of the LiQD Cornea was a response to a challenge from Tej Kohli to Griffith and Allan on how they can expect to reach millions as solid implants, like donor corneas, will require expensive OR teams and time. While stem cells will be needed where these are deficient, the Montreal team and collaborators worldwide continue to work on therapies that include both biomaterials and stem cells.

The Tej Kohli & Ruit Foundation is a restricted fund operating under the auspices of Prism The Gift Fund, registered UK charity number 1099682.

Read more

Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style

Categories

  • Morning Wire Content
  • Charity
  • Tech

Related Topics

  • Charity

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

    Business Wire
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • NADclinic and GCLS Announce Strategic Collaboration in Longevity and Performance Medicine Education

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook